Fidelity Advisor Biotechnology A holds a quantitatively derived Bronze Morningstar Medalist Rating. The rating reflects that it has scored better than the norm on factors Morningstar research associates with future outperformance relative to category peers.
Fidelity Advisor Biotechnology Fund - Class A FBTAX
- NAV / 1-Day Return $45.87 / −1.42 %
- Fund Size $2.4B
- Adjusted Expense Ratio 0.940%
- Net Expense Ratio 0.940%
- Fee Level: Distribution Low
- Share Class Type Front Load
- Morningstar Category Health
- Equity Style Box (Funds) Mid Blend
- Minimum Initial Investment $0
- Investment Status Open
- TTM Yield 0.95%
- Turnover Ratio 54%
Morningstar’s Analysis FBTAX
Will FBTAX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 46.2
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
AbbVie Inc | 13.83 | 336M | Healthcare |
Gilead Sciences Inc | 6.02 | 146M | Healthcare |
Alnylam Pharmaceuticals Inc | 3.84 | 93M | Healthcare |
Insmed Inc | 3.41 | 83M | Healthcare |
Amylyx Pharmaceuticals Inc | 3.38 | 82M | Healthcare |
argenx SE ADR | 3.28 | 80M | Healthcare |
Dianthus Therapeutics Inc | 3.18 | 77M | Healthcare |
Spyre Therapeutics Inc | 3.16 | 77M | Healthcare |
Moderna Inc | 3.12 | 76M | Healthcare |
Revolution Medicines Inc Ordinary Shares | 2.98 | 72M | Healthcare |